Inställningar

Split view

Short keys for navigating in split view

↑	Select newer press release
↓	Select older press release
←	Navigate backwards
→	Navigate forward
Enter	Navigate to line in focus
Tab	Focus next link
A or 1	Open First attachment
S or 2	Open Second attachment
D or 3	Open Third attachment
F or 4	Open Fourth attachment
I	Show company information
PgUp	Select newest press release
PgDown	Select oldest press release
L	Focus on filer bar
N	Increase preview window size
M	Decrease preview window size
Esc	Escape from mode

Dark Mode

Set dark mode to MFN.se

Sound

Plays a notification sound when new press release is published in the current feed

Intresserad av platformen MFN för nyhetsdistribution?

Fredag 14 Mars | 13:05:50 Europe / Stockholm

Svenska | English

BioStock

Alligator Bioscience: BioStock: Alligator's CEO: "We are not surprised by the positive readout"

2025-03-03 15:18:00

Lund-based Alligator Bioscience continue to strengthen the case for their phase II candidate mitazalimab with 24-months data. BioStock reached out to CEO Søren Bregenholt to get his comments on the updated data.
- These results align well with our expectations and further reinforce our confidence in mitazalimab's potential, says Bregenholt.

Read the full article at biostock.se:

Alligator's CEO: "We are not surprised by the positive readout"

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

BioStock

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden